GlassScriptPhysician profile
Ivan R Landan
NPI 1659341295
$24,518.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $215.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23,282.18 | 2019-2020 | |
| Biogen, INC. | $502.06 | 2019-2020 | |
| Emd Serono, INC. | $263.41 | 2019 | |
| Acorda Therapeutics, INC | $103.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.60 | 2019 | |
| Neurocrine Biosciences, INC. | $65.25 | 2019-2020 | |
| Kyowa Kirin, INC. | $40.51 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.34 | 2019-2020 | |
| Lilly USA, LLC | $29.85 | 2019 | |
| Abbott Laboratories | $27.66 | 2019 | |
| Acadia Pharmaceuticals INC | $19.14 | 2019 | |
| Csl Behring | $16.67 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.21 | 2020 | |
| Genentech USA, INC. | $14.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.82 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $14.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Landan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.